Establishment of a Biobanking Network as a Sustainable Mechanism to Accelerate Development and Evaluation of Diagnostic Tests in Africa

  • Version
  • Download 3125
  • File Size 395.92 KB
  • File Count 1
  • Create Date 30 September 2020
  • Last Updated 30 September 2020

Establishment of a Biobanking Network as a Sustainable Mechanism to Accelerate Development and Evaluation of Diagnostic Tests in Africa

Purpose of the the Biobanking NetworkOutbreaks of infectious diseases are occurring with increasing frequency and unpredictability. The rapid development and deployment of diagnostics that can accurately and quickly identify pathogens as part of epidemic preparedness is essential, including now for the COVID-19 pandemic. Although the past two decades have seen rapid advances in diagnostic technologies, access to well-characterized specimens remains a significant barrier to test development and evaluation in Africa.
Nevertheless, the past ten years have seen investment to build highquality sustainable biorepositories within the continent. To accelerate access to quality-assured diagnostics in Africa nations, the Africa Centres for Disease Control and Prevention (Africa CDC) has launched the African Collaborative Initiative to Advance Diagnostics (AFCAD).
Under the initiative, Africa CDC proposes to build on existing structures to establish a network of biobanks that facilitate and accelerate the development, evaluation and research on the diagnostics required for disease control and prevention programmes in the region.
The current document presents a sustainable model for a regional network of country-owned biobanks incorporating standardized methods for collection, characterization and archiving of specimens, and characterization of isolates to facilitate and accelerate diagnostics development and evaluation for COVID-19 and other diseases of epidemic potential. The Biobanking Network should be managed according to the guiding principles of transparency, equitable access,
ethics, and respect for national laws that support country ownership and sustainability. By adapting the Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity,1 sharing of specimens from national biobanks can be rewarded through mechanisms such as equitable access to diagnostics.

 

 

Attached Files

FileAction
Establishment of a Biobanking Network - ENGDownload

This slide deck, presented at the Developing Countries Vaccine Manufacturers Network International Annual General Meeting in October 2024, describes updated results from a study to assess the current and planned state of vaccine manufacturing in Africa and provides insights into what’s needed to develop a robust and sustainable vaccine manufacturing ecosystem.

We surveyed African vaccine manufacturers to better understand their current manufacturing capacity and capabilities, the progress they’ve made since 2023, and their future outlooks. This information can help stakeholders and funders better coordinate and prioritize actions to build a successful African vaccine manufacturing ecosystem.

Corporate author(s): Africa Centres for Disease Control and Prevention (Africa CDC); Clinton Health Access Initiative (CHAI); PATH

Publication date: October 2024

Download Files
FileAction
African Vaccine Manufacturing Mapping | Supply and Demand LandscapeDownload